(R)-3-O-Methyldopa-d3 hydrochloride

Modify Date: 2024-01-23 19:03:32

(R)-3-O-Methyldopa-d3 hydrochloride Structure
(R)-3-O-Methyldopa-d3 hydrochloride structure
Common Name (R)-3-O-Methyldopa-d3 hydrochloride
CAS Number 2714485-35-3 Molecular Weight 250.69
Density N/A Boiling Point N/A
Molecular Formula C10H11D3ClNO4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of (R)-3-O-Methyldopa-d3 hydrochloride


(R)-3-O-Methyldopa-d3 hydrochloride is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

 Names

Name (R)-3-O-Methyldopa-d3 hydrochloride

 (R)-3-O-Methyldopa-d3 hydrochloride Biological Activity

Description (R)-3-O-Methyldopa-d3 hydrochloride is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  

[2]. Asanuma M, Miyazaki I. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. BMC Neurosci. 2016 Jul 25;17(1):52.  

 Chemical & Physical Properties

Molecular Formula C10H11D3ClNO4
Molecular Weight 250.69